Learn More
CD309 (FLK1) Monoclonal Antibody (Avas12a1), eBioscience™, Invitrogen™
Rat Monoclonal Antibody
69.00 EUR - 279.00 EUR
Specifications
Antigen | CD309 (FLK1) |
---|---|
Clone | Avas12a1 |
Concentration | 0.5 mg/mL |
Applications | Flow Cytometry, Immunohistochemistry, Western Blot |
Classification | Monoclonal |
Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
---|---|---|---|---|---|---|---|---|---|
Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
15277487
|
Affymetrix eBioscience
14-5821-82 |
100 μg |
129.00 EUR
100µg |
Estimated Shipment: 11-06-2024 Log in to see stock. |
Please sign in to purchase this item. Need a web account? Register with us today! | ||||
15287487
|
Affymetrix eBioscience
14-5821-85 |
500 μg |
279.00 EUR
500µg |
Estimated Shipment: 11-06-2024 Log in to see stock. |
Please sign in to purchase this item. Need a web account? Register with us today! | ||||
15267487
|
Affymetrix eBioscience
14-5821-81 |
50 μg |
This item is currently unavailable or has been discontinued. View the product page for possible alternatives. |
||||||
Description
Description: The Avas12a1 monoclonal antibody reacts with mouse Flk-1, also known as vascular endothelial growth factor receptor 2 (VEGFR2). Flk-1 is a receptor tyrosine kinase involved in vascular endothelial tissue development and is expressed on endothelial cells during embryonic stages and some endothelial tissues in the adult. Applications Reported: The Avas12a1 antibody has been reported for use in flow cytometric analysis, immunoblotting (WB), and immunohistochemical staining. Applications Tested: This Avas12a1 antibody has been tested by flow cytometric analysis of bEnd.3 cells. This can be used at less than or equal to 0.5 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.
KDR (FLK1, VEGFR2) is a type III receptor tyrosine kinase. It binds vascular endothelial growth factor with high affinity in vitro, and is expressed early in development by endothelial cell precursors. FLK1 (VEGF Receptor 2) encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc. Mutations of FLK1 (VEGF Receptor 2) are implicated in infantile capillary hemangiomas.Specifications
CD309 (FLK1) | |
0.5 mg/mL | |
Monoclonal | |
Liquid | |
RUO | |
P35918 | |
IgG2a κ | |
Affinity chromatography | |
Antibody |
Avas12a1 | |
Flow Cytometry, Immunohistochemistry, Western Blot | |
Unconjugated | |
Rat | |
Mouse | |
16542 | |
Primary | |
4° C |
For Research Use Only.